COTQF (Cotinga Pharmaceuticals) Accounts Payable : $0.00 Mil (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Accounts Payable?

Cotinga Pharmaceuticals's Accounts Payable for the quarter that ended in Jan. 2020 was $0.00 Mil.

Cotinga Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Cotinga Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Accounts Payable Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Accounts Payable

Get a 7-Day Free Trial

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Accounts Payable	Get a 7-Day Free Trial															-	-	-	-	-

Cotinga Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Cotinga Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019